Novo’s next-gen obesity bet enters Korea phase 3 as Wegovy leads local market
Wegovy (semaglutide) has become one of the leading obesity drugs in Korea, and Novo Nordisk is now expanding its next obesity candidate into Korean hospitals through two late-stage, multinational trials of amycretin. Korea’s Ministry of Food and Drug …